WO2004047853A3 - Procedes de traitement de douleurs chroniques et compositions associees - Google Patents

Procedes de traitement de douleurs chroniques et compositions associees Download PDF

Info

Publication number
WO2004047853A3
WO2004047853A3 PCT/EP2003/013114 EP0313114W WO2004047853A3 WO 2004047853 A3 WO2004047853 A3 WO 2004047853A3 EP 0313114 W EP0313114 W EP 0313114W WO 2004047853 A3 WO2004047853 A3 WO 2004047853A3
Authority
WO
WIPO (PCT)
Prior art keywords
chronic pain
esdn
methods
treat
treatment
Prior art date
Application number
PCT/EP2003/013114
Other languages
English (en)
Other versions
WO2004047853A2 (fr
Inventor
Pamposh Ganju
Chuanzheng Song
Robert William Terry
William Leonard Wishart
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Pamposh Ganju
Chuanzheng Song
Robert William Terry
William Leonard Wishart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Pamposh Ganju, Chuanzheng Song, Robert William Terry, William Leonard Wishart filed Critical Novartis Ag
Priority to AU2003293714A priority Critical patent/AU2003293714A1/en
Publication of WO2004047853A2 publication Critical patent/WO2004047853A2/fr
Publication of WO2004047853A3 publication Critical patent/WO2004047853A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne la ESDN en tant que cible appropriée pour la mise au point de nouvelles thérapeutiques pour traiter ou atténuer des douleurs chroniques. L'invention concerne des procédés permettant de traiter et/ou d'atténuer des douleurs chroniques ainsi que des compositions pharmaceutiques destinées à cet effet, contenant des modulateurs ayant une action inhibitrice de l'activité et/ou de l'expression génique de la ESDN. L'invention concerne également un procédé permettant d'identifier des composés thérapeutiquement utiles pour traiter des douleurs chroniques, qui consiste à identifier des composés susceptibles d'inhiber l'activité de la ESDN et/ou son expression génique et d'inverser les effets pathologiques des douleurs chroniques in vivo.
PCT/EP2003/013114 2002-11-22 2003-11-21 Procedes de traitement de douleurs chroniques et compositions associees WO2004047853A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003293714A AU2003293714A1 (en) 2002-11-22 2003-11-21 Methods for the treatment of chronic pain and compositions therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42862202P 2002-11-22 2002-11-22
US60/428,622 2002-11-22

Publications (2)

Publication Number Publication Date
WO2004047853A2 WO2004047853A2 (fr) 2004-06-10
WO2004047853A3 true WO2004047853A3 (fr) 2004-07-15

Family

ID=32393434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/013114 WO2004047853A2 (fr) 2002-11-22 2003-11-21 Procedes de traitement de douleurs chroniques et compositions associees

Country Status (2)

Country Link
AU (1) AU2003293714A1 (fr)
WO (1) WO2004047853A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010008051A1 (fr) 2008-07-16 2010-01-21 株式会社医学生物学研究所 Anticorps anti-clcp1 humain et son utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129697A1 (en) * 2001-12-27 2003-07-10 Ono Pharmaceutical Co., Ltd. Novel polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129697A1 (en) * 2001-12-27 2003-07-10 Ono Pharmaceutical Co., Ltd. Novel polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOBUKE ET AL: "ESDN, a novel neuropilin-like membrane protein cloned form vascular cells with the longest secretory signal sequence amoung eukaryotes is up regulated after vascular injury", J.BIOL.CHEM, vol. 276, no. 36, 2001, pages 34105 - 34114, XP002272244 *

Also Published As

Publication number Publication date
AU2003293714A1 (en) 2004-06-18
WO2004047853A2 (fr) 2004-06-10

Similar Documents

Publication Publication Date Title
WO2003020287A3 (fr) Methodes de traitement de douleurs chroniques et compositions correspondantes
WO2006124892A3 (fr) Modulateurs de la toxicite induite par l'alpha-synucleine
WO2005021558A3 (fr) Inhibiteurs de proteasomes et procedes d'utilisation de ceux-ci
WO2005016859A3 (fr) Inhibiteurs de proteasome et methodes les utilisant
WO2006002262A3 (fr) Genes et voies exprimes de maniere differentielle dans des troubles bipolaires et/ou troubles depressifs majeurs
WO2006023649A3 (fr) Traitement de la sclerose en plaques grave
WO2004048551A3 (fr) Cible destinee a la therapie d'un trouble cognitif
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
WO2004022580A3 (fr) Peptides bh3 et leur methode d'utilisation
WO2005034940A3 (fr) Inhibiteurs doubles d'alanyl-aminopeptidase et de dipeptidylpeptidase iv utilises pour influer de maniere fonctionnelle sur differentes cellules et pour traiter des affections immunologiques, inflammatoires, neuronales et autres
WO2004064728A3 (fr) Composes de tetracycline possedant des activites therapeutiques ciblees
WO2004010937A3 (fr) Methode de traitement du cancer
WO2006037462A3 (fr) Marqueurs du cancer
WO2004098377A3 (fr) Procedes et compositions pour le diagnostic et la therapie de troubles lies a la parkine
WO2000038666A3 (fr) COMBINAISON D'INHIBITEURS DE LA FBPase ET DE SENSIBILISANTS A L'INSULINE, POUR LE TRAITEMENT DU DIABETE
WO2007117560A3 (fr) Pipéridine et morpholine inhibiteurs de la rénine
WO2005089496A3 (fr) Procédés pour le traitement de synucléinopathies
PL373432A1 (en) Method for treating severe heart failure and medicament therefor
WO2007047205A3 (fr) Inhibiteurs enzymatiques du pai-1
WO2004092735A3 (fr) Methodes et compositions ciblant les tyrosine kinases pour le diagnostic et le traitement de l'osteoarthrite
WO2004073615A3 (fr) Composes de deazaflavine et leurs methodes d'utilisation
WO2006116185A3 (fr) Procedes destines au traitement de myelomes multiples
WO2003035048A3 (fr) Procedes et compositions de traitement de l'osteo-arthrite
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2003082255A3 (fr) Utilisation de mob-5 pour combattre la douleur

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX MZ NI NO NZ OM PG PH PL PT RO RU SC SE SG SK SY TJ TM TN TR TT UA US UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP